1. controversies in prostate cancer radiation therapy april 24, 2013 lancaster general health cme...
TRANSCRIPT
1
Controversies in Prostate Cancer
Radiation Therapy
April 24, 2013
Lancaster General Health CME
Curtiland Deville, MD
Assistant Professor
3
Disclosures
None
4
Outline
Objective: to review current controversies and hot topics in prostate RT:• Background• Conformality
– 3DCRT vs. IMRT• Motion management (IGRT)• Dose escalation
– Hypofractionation– SBRT
• Modality – Proton vs. IMRT
5
Outline
Controversies and Hot Topics in Prostate RT (not covered):• Erectile dysfunction prophylaxis using a PDE-5 inhibitor• Brachytherapy:
– Role in high risk prostate cancer– Benefit of androgen deprivation (ADT)
• Post-prostatectomy RT– Adjuvant vs. early salvage
• Clinically node positive (N1M0)– Benefit of definitive RT with ADT
• Intermediate risk prostate cancer– Benefit of short-term ADT in the setting of dose escalation
• High risk prostate cancer– Benefit of elective pelvic nodal irradiation– Duration of long-term ADT (are 28-36 months needed)
6
Background
The role of radiotherapy across all risk groups as curative management for prostate cancer is well-established.
7
2D RT 3DCRT
IMRT Rapid Arc
Evolution of conformality
8
IMRT vs. 3D-CRT
No randomized trials comparing IMRT with 3D-CRT for localized prostate cancer.
Retrospective data suggest an improved toxicity profile.• Medicare Surveillance, Epidemiology, and End Results (SEER) analysis
of 12,000 men.– IMRT less GI “morbidity,” hip fractures, and additional cancer therapy
Sheets NC, et al, JAMA 2012
• MSKCC series of 1571 men – IMRT 81 Gy vs. 3D-CRT at lower doses (358 at ≤70.2 Gy and 472 at
75.6 Gy). – IMRT significantly reduced grade ≥2 GI toxicity at 10 years (5% vs.
13% 3D-CRT).Zelefsky M, et al, Red
Journal 2008
9
Motion Management
Interfraction Motion• Changes in position between fraction, “day to day”• External: set-up error• Internal: Mostly due to daily changes in rectal and bladder volume• Image-guided radiotherapy (IGRT) - daily imaging to provide prostate
localization to account variable motion
Intrafraction Motion• Changes in position while the treatment beam is on, “second by second”
10
Motion Management (pre-IGRT era)
Rectal size at RT planning prognostic for PSA-free survival
de Crevoisier, Red Journal 2005
11
Motion Management
Daily localization IGRT techniques to account for interfraction motion:• intraprostatic fiducial markers with daily imaging• transabdominal US• daily in-room CT imaging• endorectal balloon immobilization
All of these methods employ daily imaging of the prostate in the treatment room.
12
Motion Management
In this technique, the isocenter is shifted until the bony contours (setup error) or the implanted markers are in agreement (total error).
Graf, RO Journal 2009
reference (simulation film) online (port film) co-registered (right)
13
Motion Management
Cone beam computerized tomography (CBCT) allows volumetric visualization of the prostate and adjacent organs. • Daily online correction
allows for PTV margins: – 4 mm in all directions and 3
mm posterior (Pawlowski, Red Journal 2010)
– 5 mm all around and 3 mm posterior (Hammoud, Red Journal 2008)
2 stages of image registration: Top: pelvic bone region of interestBottom: prostate/sv represented by masked area.
14
Motion Management Intrafraction Motion
• Changes in position while the treatment beam is on (“second by second”)• Mostly from peristalsis/gas, pelvic floor movement, respiration coughing, etc.• Techniques to account for intrafraction motion:
– RGRT (radiofrequency-guided RT techniques)– Rectal balloon – Bowel prep (anti-gas tablets and daily bm)– Consistent Bladder filling
15
16
17
18
19
20
21
22
23
24
Motion management
Electromagnetic transponders Benefits:
• localize the prostate similar to fiducial markers but without additional radiation dose
• real-time tracking, allowing for immediate intervention if prostate moves outside the radiation field.
Limitations:• Subsequent difficulty of prostate
post-treatment follow-up with MRI• Patient factors: pacemakers,
obese/abdominal girth.
25
Motion management
Endorectal balloon • Used for prostate
immobilization/fixation • Ensures reproducibility of
rectal filling and spares posterior rectumTeh, Red Journal 2001
78 Gy IMRT plans without (left) and with balloon (right) Contours: rectal wall (green), anal wall (purple) and PTV (blue).
26
Dose escalation
Biologic models support dose escalation beyond 80 Gy
Improved conformality and IGRT techniques have allowed for dose escalation
Multiple randomized trials show improved control rates:• MD Anderson: 8-yr freedom from biochemical or clinical failure improved
significantly with dose escalation from 70 to 78 Gy (59% vs. 78%). Kuban, Red Journal 2008
• Proton Radiation Oncology Group (PROG) 95-09 collaborative trial compared 70.2 GyE to 79.2 GyE using proton beam after standard photon 50.4/28, finding significantly improved 10-year biochemical PFS.
Zietman, JCO 2010
27
Hypofractionation
Shorter courses of RT using larger treatment fractions• 2.5 - 3.1 Gy per fraction, rather than standard 1.8 - 2.0 Gy
Method of dose escalation Preliminary reports suggest similar outcomes and favorable toxicity
profiles:• Fox Chase• Cleveland Clinic• Italian NCI
28
Hypofractionation
Italian NCI randomized trial • 168 men with high-risk prostate
cancer. • 3DCRT + 9 mo ADT• 80 Gy/40 vs. 62 Gy/20 fractions • Median f/u 70 months • No differences in biochemical, local,
or distant failure (right). • No differences in toxicity.
Arcangeli, Red Journal 2010, 2012
29
Hypofractionation
Multiple multi-institutional randomized trials are ongoing:• RTOG 0415 clinicaltrials.gov NCT00331773
– Patients: cT1-T2c, PSA <10– Arms: 73.8/41 vs. 70/28– Closed: 12/2009
• Ontario Clinical Oncology Group clinicaltrials.gov NCT00304759 – Patients: Intermediate risk PCA– Arms: 78/39 vs. 60/20– Target: 1204 patients, completion by 6/2013
• UK clinicaltrials.gov NCT00392535 – Patients: cT1b-T3a, PSA <= 30, risk of SV+ <30%– Arms: 37 fxs vs. 20 fxs vs. 19 fxs– Target: 2163 men, completion by 9/2012
Long-term results are required before hypofractionation can be considered a standard alternative
30
Hypofractionation (at Penn Medicine)
Mild Hypofractionation With Proton Therapy or Intensity Modulated Radiation Therapy (IMRT) for Intermediate-Risk Prostate Cancer
70 Gy/ 28 fractions (2.5 Gy per fractions) currently recruiting Abramson Cancer Center of the University of Pennsylvania ClinicalTrials.gov Identifier: NCT01352429 Eligibility:
• Clinical stages T1a-T2c N0 M0• Gleason score must be in the range 2-7• PSA values < 20 ng/ml within 90 days prior to registration.
Androgen deprivation at discretion of the treating radiation oncologist.
31
Stereotactic Body Radiotherapy (SBRT)
Extreme hypofractionation
Entire dose is administered in a very limited number (~5) of fractions.
Requires high degree of precision in defining the target and administering the radiation• Immobilization• Imaging• Motion management
32
SBRT
33
SBRT
Longer follow-up in larger numbers of patients is required to establish the safety and efficacy of this approach
Presently SBRT should be performed within the context of a clinical trial
34
Proton Therapy vs. IMRT
35
Proton Therapy
36
Proton Therapy vs. IMRT
Dosimetric study:
10 IMRT vs.10 proton beam to 78 Gy
Mean rectal dose-volume histograms
Vargas et al. IJROBP 2007
37
Proton Therapy
38
Proton Therapy vs. IMRT
No randomized trials comparing proton therapy to photon therapy or brachytherapy in men with clinically localized prostate cancer.
Retrospective analyses have not established whether proton beam therapy (either alone or in combination with photon therapy) is less toxic than photon therapy alone or brachytherapy
39
Proton Therapy vs. IMRT (retrospective)
Medicare-SEER analysis of 684 men treated with proton therapy 2002-2007 vs. matched IMRT cohort• IMRT associated with less GI “morbidity”• No significant differences in other toxicities• No difference in additional cancer therapy
Sheets NC, et al, JAMA 2012
Medicare analysis of 421 men treated with proton therapy with 842 2008-2009 vs. matched IMRT cohort• Less GU toxicity at 6 mo for protons, which disappeared by 1 yr • No other significant differences• Proton therapy associated Medicare reimbursement costs were 75%
higher than IMRTYu JB, et al, JNCI 2013
40
Proton Therapy vs. IMRT (at Penn Medicine)
Proton Therapy vs. IMRT for Low or Low-Intermediate Risk Prostate Cancer
Currently recruiting Sponsor: Massachusetts General Hospital Collaborators:
• University of Pennsylvania• National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT01617161 Anticipated enrollment: 461 Primary Outcome Measures:
• Compare the reduction in mean EPIC bowel scores at 24 mo
41
Thank You
42